Seeking Alpha·Sep 14, 2026
Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptCabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Cabaletta Bio is a pre-revenue biotechnology company whose financial profile is entirely defined by its research and development pipeline, with operating losses widening to $52.0 million in Q2 2026 as R&D spending reached $44.4 million. The primary investment ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.34+8.8% vs -$0.37 | — vs $2M |
Q2 2026 May 14, 2026 | -$0.39+4.9% vs -$0.41 | — vs $2M |
Q2 2026 Mar 23, 2026 | -$0.40+11.1% vs -$0.45 | — vs $833,333 |
Q4 2025 Nov 10, 2025 | -$0.44+10.2% vs -$0.49 | — vs — |
Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Meetings with investors on Tuesday, September 8, 2026, in Boston, MA.
Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel
Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with strong EULAR 2026 data and a compelling $2.90/share entry point. CABA's rese-cel is advancing across five indications, with pivotal myositis and systemic sclerosis trials, clean safety profile, and automated manufacturing via Cellares. Recent $150M raise with participation from Eli Lilly and top biotech funds strengthens CABA's financial runway and strategic optionality, supporting a 2H27 BLA timeline.
Benchmark CABA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cabaletta Bio, Inc. (CABA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.22 | $361.98M | -1.35 | — | — | -126.98% | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $26.38 | $3.3B | -202.92 | 91.34% | 6.15% | 15.05% | — | |
| $36.82 | $26.6B | -85.63 | -71.57% | -3534.88% | -5.33% | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — |
Cabaletta Bio, Inc. (CABA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Cabaletta Bio, Inc. (CABA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jun 11, 2026·SEC
Jun 3, 2026·SEC
Get notified when CABA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cabaletta Bio, Inc. (CABA) stock FAQ — growth, dividends, profitability & financials explained
Cabaletta Bio, Inc. (CABA) reported a net loss of $181.3M for fiscal year 2025.
Cabaletta Bio, Inc. (CABA) has a return on equity (ROE) of -127.0%. Negative ROE indicates the company is unprofitable.
Cabaletta Bio, Inc. (CABA) had negative free cash flow of $154.2M in fiscal year 2025, likely due to heavy capital investments.
